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The inability to deliver bioactive agents locally in a transient but sustained manner is one of the chal-
lenges on the development of bio-functionalized scaffolds for tissue engineering (TE) and regenerative
medicine. The mode of release is especially relevant when the bioactive agent is a growth factor (GF),
because the dose and the spatiotemporal release of such agents at the site of injury are crucial to achieve
a successful outcome. Strategies that combine scaffolds and drug delivery systems have the potential to
provide more effective tissue regeneration relative to current therapies. Nanoparticles (NPs) can protect
the bioactive agents, control its proﬁle, decrease the occurrence and severity of side effects and deliver
the bioactive agent to the target cells maximizing its effect. Scaffolds containing NPs loaded with
bioactive agents can be used for their local delivery, enabling site-speciﬁc pharmacological effects such as
the induction of cell proliferation and differentiation, and, consequently, neo-tissue formation. This re-
view aims to describe the concept of combining NPs with scaffolds, and the current efforts aiming to
develop highly multi-functional bioactive agent release systems, with the emphasis on their application
in TE of connective tissues.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Nanostructured materials have been widely investigated in tis-
sue engineering (TE) and regenerative medicine ﬁelds [1]. Tissue
engineering and regenerative medicine research focuses mainly on
the development of strategies to promote natural tissue repair and
regeneration mechanisms [1]. The so-called triad of a TE strategy
involves the following fundamental components: cells, biomaterial
scaffolds and signaling biomolecules [2]. Commonly, a TE approach
comprises the seeding of adequate cells over or into biodegradable
and porous biomaterial scaffold, before its implantation, in order to
repopulate a defect site and/or restore tissue function [3,4]. The
cells' environment is composed of an extracellular matrix (ECM)(Direct), þ351 253 510900;
. Monteiro), amartins@dep.
Reis), nuno@dep.uminho.pt
se Society for Regenerative
ative Medicine. Production and hoand bioactive agents [5]. The most commonly used bioactive agents
in the culturing medium or included on the biomaterials scaffold
composition are the growth/differentiation factors (GFs). They are
proteins that have crucial roles in stimulating cell proliferation,
migration, differentiation and maturation of functional tissues
precursors [6,7]. A successful regenerative outcome requires a so-
phisticated tuning of the GFs concentrations at the biomaterial
scaffold, particularly at its boundary with the healthy tissue [8,9].
Thus, the modality of GFs presentation to the surrounding cells has
been recognized as a key fundamental issue in many TE ap-
proaches. The potential of NPs systems for GFs' delivery has been
perceived to protect GFs during tissue regrowth [6]. Moreover, it
offers adequate control over GFs' release rate. The development of a
highly functional release system can be achieved by the combina-
tion of NPs with biomaterial scaffolds. This review aims to present
and discuss the concept of combining NPs with biomaterial scaf-
folds and describe the current efforts to develop multi-functional
GFs release systems, with special emphasis on their application in
TE and regenerative medicine approaches to repair or regenerate
connective tissues.sting by Elsevier B.V. All rights reserved.
Fig. 2. Diagram representing the ﬂexible tailoring of new NP formulations aiming for
an intracellular delivery of therapeutic agents.
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NPs have been one of the most promising devices for improving
the delivery of bioactive agents and, consequently, increase their
therapeutic efﬁcacy [10,11]. Besides drug delivery, NPs have been
also used in in vitro diagnostics, in vivo imaging and TE [1,6,12].
Although, NPs refer to particles with size ranging between 1 and
100 nm [10], NPs also include sub-micron particles with the size
below 1000 nm [12,13].
2.1. Types of nanoparticles
Fig.1 shows examples of NPs used as carriers of bioactive agents.
Liposomes are the ﬁrst carrier system [15]. Liposomes are lipid
vesicles formed when lipids are added to an aqueous solution.
Lipids that form liposomes are amphipathic, such as phospholipids.
Amphipathic lipids have a head end (hydrophilic) that attracts
water and a tail end that repels water (hydrophobic) [16]. Lipo-
somes can be produced using several methods [17,18], being the
thin ﬁlmmethod the ﬁrst and common one. Moreover, it is possible
to prepare liposomes varying in size, phospholipid composition
and surface characteristics to suit the application for which they are
intended [15].
Polymeric NPs are probably the largest category of nanosized
materials used in the drug delivery ﬁeld [19]. Synthetic polymers
such as polylactides, poly(lactic acid) (PLA), poly(ε-caprolactone)
(PCL), polyethylene glycol (PEG), and poly(DL-lactide-co-glycolide)
(PLGA) have beenwidely used for the preparation of NPs. However,
NPs made from natural-origin polymers such as albumin, alginate,
chitosan, dextran and heparin have also been explored. They pre-
sent many advantageous properties such as biodegradability,
biocompatibility with physiological systems, natural abundance,
and suitability for chemical modiﬁcations and blending with the
synthetic polymers [11,14,20]. Depending on the preparation
method, nanospheres or nanocapsules can be obtained. Nano-
capsules are vesicular systems in which the bioactive agent is
conﬁned to a cavity surrounded by a polymer membrane; while
nanospheres are matrix systems in which the bioactive agent is
physically dispersed [20,21]. Other systems based on polymers
include micelles and dendrimers. Polymeric micelles are based on
amphiphilic block copolymers, which assemble to form a nano-
sized structure in aqueous media [22]. Dendrimers are highly
branched, globular polymeric materials with nanometer-scale di-
mensions. They are deﬁned by three components: a central core, an
interior dendritic structure (the branches), and an exterior surface
with functional surface groups [23,24].
2.2. Properties of nanoparticles
The properties of NPs have beenwidely studied and reviewed in
the literature [1,21,25,26]. Composition, physical properties, surface
chemistry and targeting ligands are among the parameters that can
be manipulated to enhance the efﬁciency of the carriers (Fig. 2) [1].Fig. 1. Examples of NPs used in drug dIn fact, their nanoscale properties determine the diffusivity, bio-
distribution, biological fate, toxicity and the targeting ability [14].
The nanoscale dimension also increases the surface area to volume
ratios, which increases the surface reactivity, drug loading ability,
bioavailability and the release of loaded bioactive agents [13,19].
Moreover, they improve transport properties due to their ability to
penetrate into tissues through capillaries and epithelial lining, and
allow a more efﬁcient delivery of therapeutic agents to target cells
[14]. NPs can accumulate more than 10e200 times into tumor tis-
sue than normal tissue due to the enhanced permeation and
retention (EPR) effect [27e30]. EPR effect is a phenomenon that
occurs in solid tumors, where macromolecules with molecular
weight larger than 40e50 kDa or NPs are selectively retained in
tumor tissues for longer time [30]. This effect occurs more in tu-
mors than healthy tissues, because tumor blood vessels are char-
acterized by poorly adherent endothelial cells with wide
fenestrations and the lack of a smooth muscle cell layer. EPR effect
is a “gold standard” for the anticancer drug design and for targeting
sites of tissue inﬂammation [27e30]. Targeting to speciﬁc tissues is
the most promising attribute of the NPs [14,31,32]. Therefore, to
reach that capability, it is needed the covalent attachment of a
deﬁned ligand at the surface of the NP, which will speciﬁcally
interact with antigens or receptors expressed at the surface of the
target cells [33]. Another relevant property of NPs is the possibility
of developing stimuli responsive release systems [34,35]. A variety
of stimuli such as pH [36], temperature [37], ultrasonic waves [38],
magnetic ﬁelds [39,40] and light [41] are currently being investi-
gated to improve the release of bioactive agents.elivery. Adapted from Refs. [10,14].
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properties, some of those characteristics also represent difﬁculties.
For instance, due to the high surface area, which results in high
surface Gibbs energy, it is extremely challenging to prevent particle
agglomeration and consequent formulation instability [42]. More-
over, they might present some stability issues such as sedimenta-
tion [43]. Others parameters can inﬂuence the fate of NPs such as
shape, charge and surface chemistry [1,25]. These parameters are
difﬁcult to control independently. Therefore, it is difﬁcult to deﬁne
general procedures on the production of NPs for optimal cellular
uptake. Indeed, it was systematically investigated the inﬂuence of
NPs' properties on cellular toxicity [44].
The NPs cytotoxicity varies based on exposed cell type and NPs
composition and size. Although the majority of NPs cytotoxicity
studies rely on in vitro cell culture data, those might not correspond
to the in vivo scenario [1,45]. One of the major obstacles to the
in vivo use of NPs is the opsonization phenomenon. NPs in contact
with biological ﬂuids are rapidly covered by biomolecules which
confers a new identity to the NPs [46,47]. Besides the size of the
NPs, their surface hydrophobicity determines the amount of
adsorbed proteins at the surface [21]. One method to improve their
surface properties is to coat the NPs with a hydrophilic polymer,
such as PEG or chitosan [26,48e50]. However, cumulative experi-
ence has revealed that, upon repeated administration, PEGylated
NPs lose their ability to circulate over long periods of time in the
bloodstream [33]. This phenomenon is known to accelerate the
clearance of NPs from the blood and it is explained by the formation
of a robust shell of proteins which is called “corona” [51]. This
robust shell arises at the surface of all NPs, even the ones designed
to avoid its formation upon contact with biological ﬂuids [51].
Coating of the surface of NPs with derivatized proteins during the
fabrication process may be one strategy to overcome this problem.
One of the important step in NPs development is sterilization.
There are several techniques to remove contaminations from NPs,
including ﬁltration, autoclaving and irradiation, formaldehyde,
ethylene oxide and gas plasma treatments [52]. Filtration, through
the use of 0.22 mm membrane ﬁlters is the commonly used tech-
nique to sterilize nanoparticles, without altering the physico-
chemical properties of the carrier nanoparticles, nor affecting their
toxicity and functionality. However, it may not be used if the NPs
are larger than, or close to, the pore size of the ﬁlters since clogging
can occur resulting in a decreased yield. Moreover, no single pro-
cess may be applied to all NP preparations and, therefore, it is
recommended that each NP system be validated on a case-by-case
basis [52].
2.3. Interaction between cells and nanoparticles
A key element for the success of NPs-based delivery system is
their ability to either cross the physiological barriers by themselves
or allow the loaded bioactive agent to transpose those physiological
barriers to achieve an optimal pharmacological action at the
pathological sites. Depending on the application, namely on the
administration route and on the target cells, NPs may have to cross
different physiological barriers in their journey towards their target
[53]. The internalization of the NPs can be categorized into two
different mechanisms, depending on the physical state of the
internalized particle [11,78]. The ﬁrst one is phagocytosis, which
corresponds to the uptake of large, solid or solid-like bodies, for
example, bacteria, debris from an implant, or collagen ﬁbers. The
second one is the endocytic pathway (e.g., micropinocytosis, and
clathrin- and calveolae-mediated endocytosis) which is a general
name for the uptake of a ﬂuid volume. Pinocytic processes are
subdivided further into mechanisms that allow the uptake of large
volumes of extracellular ﬂuid, and those that govern the uptake ofsmall volumes (clathrin-dependent and non-clathrin-dependent
mechanisms) [78,79]. The cellular internalization behavior and
cell viability differs from cell types, incubation time, NPs concen-
tration and NPs properties such as composition, size and surface
charge [44,80e84].
3. Scaffolds and nanoparticles
A scaffold provides a physical support for the development of
tissues, intending to mimic the function of the natural ECM. Tissue
Engineering strategies based on the combination of bioactive
agent-loaded NPs and scaffolds has remarkably grown in recent
years, leading to signiﬁcant advances in the ﬁeld of Tissue Engi-
neering and Regenerative Medicine [6]. Controlled release of
bioactive agents from biodegradable scaffolds can enhance the ef-
ﬁcacy of TE approaches [6]. In fact, scaffolds can be used as bioactive
agent reservoirs combined with the delivery cells [85]. They pro-
vide a multitude of advantages such as safe delivery proﬁle, pro-
tection of bioactive agents from bio-degradation and the ability to
deliver the bioactive agents locally where the cells are attached.
This type of multi-functionalized system may have an important
role in creating a highly regulated network of signals able to
orchestrate cell proliferation, migration, and differentiation, in or-
der to ﬁnally contribute to the development of a fully functional
tissue.
3.1. Properties and type of scaffolds
The physical aspects and composition of the biomaterial scaffold
depend largely on the intended application. Several natural and
synthetic polymers have been used to produce TE scaffolds [86,87].
The main requirements of these materials to be use in TE scaf-
folding are: they must be inherently biocompatible, biodegradable
and facilitating cell adhesion. Additionally, the biomaterial scaffolds
must be porous, to allow cell colonization and migration, and me-
chanically stable, allowing their manipulation, adaptation and
integration with the defect site. Indeed, cell fate showed to be
strongly inﬂuenced by the substrate rigidity, leading to enhanced
cell spreading [88]. Therefore, cells not only sense applied me-
chanical forces, but also sense the mechanical properties of their
environment, such as the elasticity of the substrate on which they
grow [89e91]. Substrate stiffness inﬂuences cells adhesion, degree
of spreading, proliferation and differentiation [89,92].
The major advantage of using natural-based over synthetic
scaffolds is the possibility to tune their degradation, which can be
readily achieved by varying the concentration of the polymer and/
or the cross-linking agents. The most used natural polymers in TE
scaffolding include ﬁbrin, collagen, gelatin, chitosan, poly-
hydroxyalkanoates, alginate and hyaluronic acid [93]. Synthetic
scaffolds have been also suggested mainly because of their pro-
cessing ﬂexibility, being possibly manufactured in many desired
shapes and sizes, with a predeﬁned architecture and structural
parameters [85,87]. The most used biodegradable synthetic poly-
mers for TE scaffolding include polyesters (PLA, PGA, PCL and
PLGA), PEG and its derivatives poly(fumarate)s and their co-
polymers with PEG, poly(vinyl alcohol), poly(amido-amines) or
poly(urethane s). Inorganic materials such as calcium phosphate
ceramics and cements, bioactive glass and ceramic/polymer com-
posites have been especially developed for bone TE [94,95]. The
manufacturing methods of polymeric 3D scaffold for TE applica-
tions have been widely reviewed in the literature [5,86,96,97]. The
conventional methods include ﬁber bonding, melt molding, solvent
casting, particulate leaching, gas foaming, phase separation, high-
pressure processing, electrospinning and rapid prototyping [5,86].
Hierarchical ﬁbrous-based scaffolds were also developed as 3D
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nation of micro- and nano-motifs, produced by rapid prototyping
and electrospinning techniques. Some TE scaffolds have been also
produced with nanofabrication techniques that create porous and
nanometer-sized features that inﬂuence cell fate, allowing regula-
tion of speciﬁc gene and protein expression patterns [100,101].
Surface-patterning techniques involve a wide range of fabrication
methods that include electron-beam lithography, nano-imprint
lithography, photolithography including micro electrical mechani-
cal systems, nano-contact printing, micromachining and three-
dimensional printing [101]. Hydrogels are a particular class of
materials that present a huge potential for application in TE as
smart and stimuli responsive systems [102,103].
Electrospinning is a simple and versatile technique enabling to
produce polymeric ultraﬁne ﬁbers with diameters ranging from a
few micrometers to tens of nanometers, having a high surface area
to volume ratio [96,104]. Electrospun nanoﬁber meshes (NFM) have
received much attention because of their physical similarity to
natural ECM and therefore demonstrating potential as biomedical
devices, TE scaffolds and drug delivery carriers [104]. Polymeric
NFMs exhibit unusual properties such as ﬂexibility in surface
functionalities, high microporosity and superior mechanical prop-
erties [96]. Fig. 3 shows a strategy to control stem cell differentia-
tion by tailoring the surface chemistry of TE scaffolds, in particular
case of nanoﬁber meshes.
3.2. Surface modiﬁcation, functionalization and immobilization
The surface of biomaterial scaffolds is of particular importance,
because it can directly affect cellular response and, ultimately, the
tissue regeneration [87]. An ideal TE scaffold should mimic the
natural ECM and interact positively with culturing cells, enhancing
the cell adhesion, proliferation, migration and differentiation. The
presence of few functional groups on the synthetic polymers leads
to the poor efﬁciency of those scaffolds in conducting a good
interface with living cells. Thus, modiﬁcation of the synthetic bio-
materials to improve their biocompatibility is necessary [105].
Several techniques have been used to modify the surface of syn-
thetic biomaterial scaffolds [104] such as plasma treatment [106],
UV irradiation [107,108], chemical methods [109], surface graft
polymerization [110], and co-electrospinning of active agents and
polymers [111]. Consequently, functional groups, such as primary
amine and carboxyl groups, can be created at the biomaterialFig. 3. Strategy to control stem cell differentiation by tailoring the surface chemistry of
electrospun nanoﬁber meshes.scaffolds' surface. These functional groups can be further used to
immobilize bioactive agents and loaded NPs [107,108,112e115].
Furthermore, the surface functionalization (surface chemistry and
energy) of biomaterial scaffolds can inﬂuence the MSCs in vitro
behavior [116]. One way to increase the interaction between the
scaffolds' surface and the culturing cells is to immobilize NPs onto a
surface to increase the effective surface area [25]. NPs can be
immobilized in speciﬁc regions of the scaffold [117,118] and
patterned over polymeric surfaces by various techniques such as
printing, micro ﬂuidics and layer-by-layer assembly [119,120]. It
was demonstrated that cells over the scaffold may expose an
increased proportion of their basal surface, creating a larger area for
NPs to attach and to be internalized. It was reported that adhesive
behavior is highly dependent on both the surface morphology and
the surface chemistry of the substrate [121].
3.3. Delivery of bioactive molecules mediated by nanoparticles
combined with scaffolds
The biomaterial scaffolds have an important role as a support for
cells in culture. However, a biomaterial scaffold alone has a limited
ability to fully differentiate transplanted stem cells [1,85]. To induce
the differentiation of transplanted stem cells, several methods of
carrying bioactive agents have been proposed [122]. One strategy
relies on the incorporation of bioactive agents directly into the
scaffold during or after the scaffold production. However, the
bioavailability of bioactive agents is generally poor since they are
poorly absorbed and have a short half-life, due to the enzymatic
degradation and self-aggregation [66,123]. Some important ad-
vantages of combining TE scaffolds with bioactive agent-loaded
NPs are: (i) the possibility and ﬂexibility of a sustained release,
(ii) protection of the bioactive agent from the physiological
degradation and (iii) reduction of side effects. Bioactive agent-
loaded NPs can be incorporated into scaffold in order to enhance
their biofunctionality, providing the biochemical cues to stimulate
tissue regeneration [1,8]. For example, NPs can be conﬁned within
the scaffold and only become available upon cell mediated degra-
dation of the scaffold [120]. In another concept, cells can be seeded
on top of the NPs that have been previously immobilized onto a
surface or the NPs can be added to previously seeded cells. NPs
immobilization is believed to maximize bioactive agent efﬁciency
by increasing the local concentration of those bioactive agents at
the cell surface [124e126]. Other studies proposed sustained
release systems that use liposomes loaded with proteins incorpo-
rated into ﬁbrin sealant [127e130]. Another approach for creating a
sustained release system relies on the adsorption of NPs onto the
surface of biomaterial scaffolds [117,131e134]. Several strategies
have been developed to facilitate the NPs adsorption to the scaffold
surface, including the speciﬁc binding of NPs through the bio-
tineavidin interaction, by the gelatin entrapment or by nonspeciﬁc
adsorption [25,117,133]. Those systems are able to transfect higher
number of cultured cells, while reducing the amount of plasmid
DNA required. MSCs cultured on collagen sponge and PET non-
woven 3D scaffolds combined with reverse transfection system
(substrate-mediated transfection) exhibited a high and sustained
transgene expression level [135]. Another important class of
bioactive agents loaded into NPs and subsequently combined with
biomaterial scaffolds are the growth factors (GF) [124e126,136].
3.4. Effect on proliferation, migration and differentiation of stem
cells
Physicochemical modiﬁcation of biomaterial scaffolds can
directly inﬂuence stem cell behavior by altering substrate proper-
ties, surface interactions, scaffold degradation rate,
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signal transduction pathways of stem cells [87]. The loading of
bioactive agent into NPs is one of the most promising strategies to
improve the efﬁciency of bioactive agent delivery, inducing the
differentiation of stem cells. Furthermore, it was demonstrated
that, when bioactive agents are entrapped within NPs, they can be
protected from physiological degradation [137]. Scaffolds combined
with bioactive agents-loaded NPs are being developed in order to
display and deliver regulatory signals to surrounding stem cells in a
precise and near-physiological fashion. This multi-functionalized
systems serve as powerful artiﬁcial microenvironments to study
and direct stem-cell fate, both in in vivo culture and in in vivo post-
implantation [8,138,139]. Decelluarized valve scaffolds modiﬁed
with TGF-b1-loaded PEG NPs showed good adhesion and growth of
myoﬁbroblasts from rats [124]. Also, MSCs were shown to prolif-
erate in 3D collagen and chitosan porous scaffold impregnatedwith
EGF-loaded chitosan NPs [125]. VEGF loaded heparin/chitosan NPs
immobilized in decellularized scaffolds stimulated endothelial cell
proliferation in vitro and signiﬁcantly increased ﬁbroblast inﬁltra-
tion, ECM production and vascularization in a mouse subcutaneous
implantation model [126]. Dex-loaded dendrimer NPs combined
with hydroxyapatite/starchepolycaprolactone scaffolds showed
osteogenic differentiation of rBMSC [67e69]. Biological results
showed that the pre-incubation of stem cells with dendrimer NPs
allows the delivery of Dex inside the cells and directly inﬂuences
their cellular fate, being a promising tool to be used in cell-based
and TE strategies [68].
3.5. Multiple release
Based on the understanding of the normal tissue repair, com-
binations of bioactive agents may have potential to enhance the
cellular and molecular events of wound healing. Substantial and
signiﬁcant work showed that ‘cocktails’ of GFs can have additive
and, possibly, synergistic effects on the proliferation, differentia-
tion, and histological activity of various cell types both in vitro and
in vivo [140]. These GFs can accelerate and enhance tissue regen-
eration. The production of GFs varies over time, which indicates the
complex and interconnected contribution of various GFs in the
development osteogenesis [141]. One of the challenges in the Tis-
sue Engineering and Regenerative Medicine ﬁeld is the develop-
ment of sophisticated delivery systems with multiple
functionalities. Extraordinary progress has been made over the last
decade towards the design of scaffolds with a suitable multi-scale
hierarchical structure and release proﬁle of GFs [142]. The current
regenerative strategies employ biomaterial scaffolds with an
external shape and an internal porous architecture, speciﬁcally
designed for ﬁtting the tissue defect and with an appropriate
bioactive component (i.e. GFs, cytokines or genes) selected to
promote functional tissue restoration [1,122,143]. Combining NPs
with scaffolds also provides several additional advantages such as
the possibility to deliver multiple bioactive agents simultaneously
or sequentially or to create spatial and temporal patterns of
bioactive agent delivery [85,144,145]. Those systems may be
particularly useful in diseases in which multiple bioactive agents
are involved or in which the local restoration of a speciﬁc bioactive
agent function can result in a therapeutic beneﬁt [1,85]. A dual GFs-
loaded polyion complex NPs-hydrogel system showed a faster
release of BMP-7 and a slower release of TGF-b2 at the end of an
incubation period of 21 days [146]. PLGA and poly(3-
hydroxybutyrate-co-3-hydroxyvalerate (PHBV) NPs providing the
release of BMP-2 and BMP-7 incorporated into PCL scaffolds
showed a sequential delivery of the two GFs [138]. The successful
simultaneous delivery of two reporter genes (galactosidase and
ﬁreﬂy luciferase) by a ﬁbrinelipoplex model system was alsosuccessfully demonstrated [144]. Furthermore, BMSCs transfected
with plasmid pIRES-hBMP-2-VEGF could secret a high level of BMP-
2 and hVEGF [147].
3.6. Applications of tissue engineering strategies combining
scaffolds and nanoparticles
Certain tissues in the body are able to initiate regeneration or
repair after injury whereas some others lack this physiological
capability (e.g. cartilage, heart muscle, central nervous system). In
the ﬁrst circumstance, the cells need a speciﬁc micro-
environmental context to proliferate and differentiate with the
ultimate goal of repairing the defect [6]. Since the frequency and
relevance of pathological situations involving bone and cartilage,
the scientiﬁc community is actively pursuing progress in the con-
trol of the regeneration and healing of these tissues [93,148]. Sig-
niﬁcant progress has been made in the development of surgical
techniques for skeletal reconstruction. Besides those, TE is one of
the most promising techniques to be used as an alternative to the
conventional autogenic or allogenic bone and cartilage trans-
plantation [149]. It is essential to develop methods that enable the
administration of bioactive agents in localized sites, at the dose and
time that mimic the physiological or pathological conditions.
Scaffolds containing NPs loaded with bioactive agents can be used
for the local delivery to enable site-speciﬁc pharmacological effects
such as the induction of cell proliferation and differentiation and,
ultimately, new tissue regeneration. Table 1 reports some examples
of scaffolds combined with bioactive agents-loaded NPs to be used
on bone and cartilage TE strategies.
3.7. In vivo application for bone tissue engineering
Bone is a living tissue, which continuously rebuilds its structure
and, therefore, has the capacity of spontaneous regeneration.
However, in case of large defects and osseous congenital de-
formities, a bone graft or a bone substitute is needed to assist and
promote the healing process. Similarly, in the case of a physical
separation between the articular surface and the bone layers or in
a very large osteochondral defect, an artiﬁcial prosthesis is
required [149]. However, osteogenesis is a complex process that
involves the synergistic contribution of multiple cell types and
various GFs. To develop effective bone TE strategies employing
GFs, it is essential to delineate the complex and interconnected
role of GFs in osteogenesis. The studies investigating the temporal
involvement of GFs in osteogenesis are limited to in vitro studies
with a single cell type or in communities of cells in vivo studies
[93]. Therefore, there is a need for platforms that incorporate the
physiological characteristics and the multicellular environment of
natural osteogenesis. TE strategies toward bone regeneration
should consider the wealth of GFs involved in osteogenesis and
their dynamical participation over time [141]. 3D scaffolds car-
rying an inherent sequential GF delivery system showed syner-
gistic effect of the GFs, holding promise for controlling bone
healing [138,154]. Undifferentiated BMSCs with BMP-2 loaded
heparin-conjugated PLGA NPs induced bone formation in mice
[167]. The sustained, prolonged release of bioactive rhBMP-7 from
PLGA NPs immobilized at nanoﬁbrous scaffolds actively induced
new bone formation in rats [136]. HA NPs combined with elec-
trospun PCL/PLLA nanoﬁber scaffolds showed to be a promising
choice for bone tissue regeneration [168,169]. Ex vivo culturing of
stromal cells with Dex-loaded dendrimer NPs combined with HA
scaffolds promotes ectopic bone formation subcutaneously on the
back of rats [67]. Hydrogels seeded with 2 million rBMSCs pre-
incubated with high dose of Dex-loaded micelles (65 mg per
million of cells) enhanced bone formation [8]. An in vivo study of
Table 1
Examples of scaffolds combined with NPs for the delivery of bioactive agents to be used in bone and cartilage TE strategies.
Application Scaffold/NP Bioactive agents Ref
year
Bone Fibrin hydrogels with heparin loaded into PLGA NPs BMP-2 [150]
2007
PLLA nano-ﬁbrous scaffolds prepared by sugar sphere template leaching and phase separation technique with PLGA NPs BMP-7 [136]
2007
PLGA/HA composite scaffolds produced by electrospinning method with pDNA/chitosan NPs BMP-2 plasmid [151]
2007
Collagen sponges reinforced PGA ﬁbers scaffold produced by the freeze-drying method with pDNA/polyethylenimine NPs BMP-2 plasmid [152]
2008
Fibrin hydrogel with heparin NPs BMP-2 [153]
2009
Chitosan-PEO scaffolds prepared by wet spinning with PLGA and PHBV NPs BMP-2 and
BMP-7
[154]
2009
Collagen sponge scaffold with PEI coated albumin NPs BMP-2 [155]
2009
Collagen sponge scaffold with PEI-PEG coated albumin NPs BMP-2 [156]
2010
PCL scaffold prepared by thermally induced phase separation with lipid based NPs siRNA [118]
2010
Polyurethane sponge HA scaffolds with dendrimers Dex [67]
2010
Gelatin hydrogels with micelles Triptolide and
BMP-2
[157]
2012
PDLLA foam scaffold produced by supercritical ﬂuid foaming with chitosan-chondroitin sulfate NPs Platelet lysates [9]
2012
Gelatin hydrogel with lactic acid oligomer-grafted gelatin micelles Dex [8]
2012
Gellan xanthan hydrogel with chitosan NPs bFGF and BMP7 [158]
2013
PCL electrospun nanoﬁber mesh with liposomes immobilized Dex [159]
2014
PCL electrospun nanoﬁber mesh with liposomes immobilized Runx2-plasmid [160]
2014
Cartilage PLGA microspheres coated with polylysine NPs TGF-b3 [161]
2008
Fibrin hydrogel mixed with heparin NPs TGF-b3 [123]
2009
PLC scaffold produced by a gel-pressing method with PLGA/Pluronic heparin NPs TGF-b1 [139]
2009
Nanoﬁbrous scaffold prepared by coaxial electrospinning with embedded liposomes TGF-b, bFGF,
IGF-I
[162]
2012
Collagen/chitosan scaffolds prepared by freeze-drying with pDNA calcium phosphate NPs TGF-b1 plasmid [163]
2012
PLGA scaffolds prepared by freeze-drying with PLGA and PNIPAM NPs IGF-I and TGF1 [164]
2013
PLLGA scaffold prepared by a carding and needle-punch process (non-woven polymer ﬁbers) with PLGA NPs. BMP4 plasmid [165]
2013
Porous Chitosan Scaffolds with hyaluronic acid and chitosan NPs TGF-b1 plasmid [166]
2013
IGF-I e Insulin-like growth factor I, TGF-b1 transform growth factor b1, PLGA e poly(lactic acid-co-glycolic acid), PNIPAM e poly(N-isopropylacrylamide), PNIPAM e poly(L-
lactic-co-glycolic acid), PLLA e poly(L-lactic acid), HA e hydroxylapatite, BMP-2 e bone morphogenetic protein-2, PGA e poly(glycolic acid), PHBV e poly(3-hydroxybutyrate-
co-3-hydroxyvalerate), PEO e poly(ethyleneoxide), PEI e polyethylenimine, PEG e poly(ethylene glycol), PCL e polycaprolactone, PDLLA e poly(D,L-lactic acid), Dex e
dexamethasone, Runx2 e Runt-related transcription factor 2, siRNA e small interfering RNA, FGF e ﬁbroblast growth factor.
N. Monteiro et al. / Regenerative Therapy 1 (2015) 109e118114wound healing using polymer matrix and pDNA showed induction
of new bone formation in a stable, reproducible, dose- and time-
dependent manner for six weeks [170]. DNA-loaded PEI NPs
encapsulated into 3D sponges enhance osteogenic differentiation
of MSCs [152]. A signiﬁcant volume bone formation was histo-
logically observed throughout the sponges seeded with trans-
fected MSC by using DNA-loaded NPs after subcutaneous
implantation into the back of rats.
3.8. In vivo application for cartilage tissue engineering
Cartilage is not a very dynamic tissue: it exhibits a low meta-
bolic rate, low turnover and long half-lives of the constituent
structural proteins [1,171]. Cartilage is composed by a low per-
centage of chondrocytes embedded in a dense nanostructured
ECM network rich in collagen ﬁbers, proteoglycans and elastinﬁbers [148]. Cartilage focal lesions resulting from trauma often
occur during sport activities. Focal defects can be either chondral
or involving the osteochondral tissue. Chondral lesions do not
affect the subchondral bone being limited to the cartilage tissue.
Since the subchondral blood vessels are not involved, these lesions
do not heal spontaneously [149]. The future generation of regen-
erative medicine for joint diseases is focused in in situ therapies
[148]. This strategy consists in cell-free chondro-inductive scaffold
implantation combined with chemotactic molecules. The main
goal is to allow the recruitment of joint-inherent and surrounding
cells to the traumatic or arthritic diseased joints, and their sub-
sequent contribution to a factor-guided joint repair. There are
some reports on GFs loaded NPs for cartilage regeneration thera-
pies [123,146,161]. However, none of those were combined with
biomaterial scaffold and, therefore, this topic is not discussed
further.
N. Monteiro et al. / Regenerative Therapy 1 (2015) 109e118 115GF loaded polyion complex NPs/hydrogel system may provide
desirable GF delivery kinetics for cartilage regeneration, as well as
the chondrogenesis of MSCs [146]. hASCs dispersed ﬁbrin gels with
TGF-b1 loaded pluronic heparin NPs seeded onto PCL scaffolds and
cultured in vitro revealed that the in situ chondrogenic differenti-
ation of the hASCs on the complex was induced and sustained by
the continuous release of TGF-b1 from the NPs [139]. In another
study, ﬁbrin constructs containing TGF-b1 loaded heparin NPs
provided a sustained level of GF for a long period of time, enabling
the formation of hyaline-like cartilage tissue in vitro and in vivo
using BMSCs [123]. Park et al. [172] also stated that transplanted
hMSCs together with TGF-b3 loaded heparin NPs may constitute a
clinically efﬁcient method for the regeneration of hyaline articular
cartilage. In another study, it was observed that the dual release of
IGF-I and TGF-b1 from PNIPAM NPs using PLGA scaffolds yielded
better results in terms of collagen type II and aggrecan expression
than GF-free and single GF-containing applications [164]. Porous
chitosan scaffolds combined with hybrid hyaluronic acid/chitosan/
pDNA NPs encoding TGF-b1were used to transfect chondrocytes
[166]. PLLGA scaffold combined with PLGA NPs delivering plasmid
encoding BMP-4 into rabbit ASCs showed that the expression of
chondrogenesis related genes and proteins was signiﬁcantly
increased in BMP-4 transfected ASCs in vitro, and BMP-4-
transfected ASCs seeded onto PLLGA scaffold signiﬁcantly
improved in vivo chondrogenesis in a rabbit articular defect model
[165].3.9. Concluding remarks
NPs and TE scaffolds can be produced from natural and synthetic
materials. NPs are used to protect, control the release proﬁle,
decrease the level of risk of having site effects and deliver bioactive
agent to the target cells. The TE scaffold serves as a support and
carrier of cells. Therefore, biomaterial scaffolds can be combined
with bioactive agents loaded into NPs to improve tissue regenera-
tion. Indeed, the NPs may interact with the scaffold and other
components of the extracellular compartment. This synergy can
inﬂuence the release of bioactive agent, the stability of the NPs and
their cellular internalization. Moreover, stem cells can be seeded
onto these multi-functionalized scaffolds and be implanted at the
injured site. The cellular signaling induced by those complexes will
inﬂuence cellular process such as attachment, proliferation,
migration and differentiation. Several studies have demonstrated
the potential of this strategy to create an advanced and functional
scaffold for bone and cartilage TE, which must sustain tissue
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